MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2024 International Congress

    Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report

    M. Khommyatov, M. Samushiya, I. Smolentseva, S. Kryzhanovskiy (Moscow, Russian Federation)

    Objective: To describe the case of a patient with paranoid schizophrenia followed by the onset of the Parkinson’s disease at the 44-year age Background: Currently…
  • 2024 International Congress

    Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies

    A. Berrio, L. Chrones, V. Abler, R. Hauser (San Diego, USA)

    Objective: To summarize the sleep and sedation-related safety and tolerability of pimavanserin for the treatment of Parkinson’s disease psychosis (PDP). Background: Pimavanserin, a 5-HT2A receptor…
  • 2024 International Congress

    Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.

    D. Ortiz-Zacarias, S. Castillo-Torres, M. Cansino-Torres, J. Trejo-Ayala, B. Chávez-Luevanos, I. Estrada-Bellmann (Monterrey, Mexico)

    Objective: To describe the clinical and demographic characteristics of patients with PDP and their relationship with the use of DAs. Background: Parkinson’s Disease Psychosis (PDP)…
  • 2024 International Congress

    Diagnostic Challenges in Functional Neurological Disorder: Convergent Psychogenic Non-Epileptic Seizures and Psychosis

    D. Nolasco, R. Holbert, B. Carr (Gainesville, USA)

    Objective: To dissect the diagnostic challenges in distinguishing Functional Neurological Disorder (FND) coexisting with psychosis, highlighting the imperative for comprehensive and nuanced neuro-psychiatric assessment. Background:…
  • 2024 International Congress

    Conceptualization of the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS) prototype.

    M. Tosin, T. Mestre, G. Stebbins, G. Mangone, S. Videmsky, S. Ali, D. Aarsland, J. Goldman, T. Khoo, S. Lewis, P. Martinez-Martin, O. Ojo, J. Pagonabarraga, A. Schrag, D. Weintraub, C. Goetz (Chicago, USA)

    Objective: To outline the process of conceptualizing the prototype for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Approximately…
  • 2024 International Congress

    Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study

    W. Cubała, A. Berrio, K. Chi-Burris, G. Alva, L. Chrones, S. Pathak (Gdańsk, Poland)

    Objective: To assess the long-term safety and tolerability of pimavanserin in frail older adults and elderly patients with neuropsychiatric symptoms related to a neurodegenerative disease…
  • 2024 International Congress

    Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period

    S. Berman, A. Willis, W. Aamodt (Philadelphia, USA)

    Objective: To determine whether antipsychotic prescriptions differ between community-dwelling and nursing home residents with PD in the last 6 months of life. Background: Most antipsychotics…
  • 2023 International Congress

    Development of an Item Bank for Assessing Psychosis in Parkinson’s Disease: A Systematic Review

    G. Mangone, M. Tosin, C. Goetz, G. Stebbins, T. Mestre (Chicago, USA)

    Objective: This study aimed to develop an item bank for assessing psychosis in Parkinson's disease (PD). Background: Psychosis is a common and debilitating symptom in…
  • 2023 International Congress

    Safety assessment of pimavanserin in Parkinson’s disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials

    G. Bano, A. Sharma (New Delhi, India)

    Objective: This systematic review and meta-analysis aimed to assess the safety profile of pimavanserin in Parkinson’s disease psychosis (PDP) patients from the available randomized controlled…
  • 2023 International Congress

    Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.

    H. Dourado, C. Lobo, G. Procópio, AE. Lima, MA. Silveira, L. de Almeida, IJ. Oliveira, G. Valença (Salvador, Brazil)

    Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley